Αποτελέσματα Αναζήτησης
Understand the peri-operative management, staging, and surgical oncology principles for cutaneous MCT in dogs and cats, and the indications for adjunctive radiation therapy or chemotherapy in conjunction with surgery.
The treatment of dogs with MCT consists of either polychemotherapy or tyrosine kinase inhibitors such as toceranib, masitinib, or, less frequently, imatinib [11,12,13]. The treatment decision is based on the clinical and histopathological diagnoses, and on the stage of the disease.
Imatinib has clinical activity against MCTs in dogs and cats. In dogs, imatinib has been shown to be an active agent in the treatment of certain cases of canine MCT, achieving complete response (CR) or partial response (PR) (10 out of 21 dogs) within 7 days (Isotani et al . 2008) (Figure 1).
7 Φεβ 2022 · This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs. Twenty-four dogs were included in the study; 13 animals were treated with IM and 11 with VP.
10 Φεβ 2022 · This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine...
7 Φεβ 2022 · This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs. Twenty-four dogs were included in the study; 13 animals were treated with IM and 11 with VP.
4 Ιουλ 2008 · Imatinib mesylate is a commercially available drug targeting protein-tyrosine kinase. Although some hepatotoxicity from imatinib mesylate has been reported in preclinical experiments using healthy dogs, 12,13 the drug is worth evaluating for treatment of canine MCT.
